Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients

Stopped early · Phase 4

Conditions studied: MRSA - Methicillin Resistant Staphylococcus Aureus Infection

In brief

Vancomycin is an essential antimicrobial which is frequently used in the ICU for suspected methicillin-resistant Staphylococcus aureus (MRSA) infection. Therefore, it is vital to optimize the dosing of vancomycin for this critically ill population. The most efficacious method of administering vancomycin is debated in the literature. Since vancomycin is associated with slow bactericidal activity, it is important to closely monitor serum concentrations so as to achieve early target serum concentration, particularly when treating aggressive S. aureus infections. One study has shown that vancomycin infused continuously may enable faster and more consistent achievement of a therapeutic serum concentration when compared to intermittent infusion. A faster achievement in the goal serum vancomycin concentration would be a protective factor for intensive care unit mortality in patients with MRSA infection. Currently in the surgical ICU (SICU) of our institute, vancomycin is administered based on a vancomycin dosing nomogram. Less than fifty percent of the ICU patients following this nomogram achieved target vancomycin concentration of 15 after 24 hours. To better achieve target vancomycin concentration in 24 hours, we developed a new vancomycin dosing nomogram with a continuous infusion. The aim is to determine which of the two dosing nomogram is more efficient and safer for SICU patients.

Key facts

Study ID

NCT01786161

Run by

Massachusetts General Hospital

People needed

44

Starts

2013-09-01

Expected to finish

2016-06-01

Last updated by the study team

2017-06-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and non-pregnant female > 18 years of age admitted to Surgical ICUs with suspected infection
• Calculated creatinine clearance > 60ml/min

You may not qualify if…

• Age < 18 years
• Allergic to vancomycin
• Calculated creatinine clearance < 60ml/min
• Pregnant
• Vancomycin administration more than 8 hour and less than 24 hour prior to study enrollment
• Anticipated vancomycin treatment less than 2 days for surgical prophylaxis

Where it is running

• MGH — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.